2013 Archived Content
Inaugural

Predictive Pre-Clinical Models in Oncology

Delivering Reproducible and Predictive Results

 

Day 1 | Day 2 | Day 3 

Thursday, February 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee





 
8:00 - 9:40 Plenary Keynote Panel: Emerging Technologies & Industry PerspectivesThis session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included. - Read more 

Sponsored by


 

 

Biocartis  Elsevier  Luminex  RemedyMD   Scientia Advisors  Singulex 

 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

 

Cell Culture Models 

10:40 Chairperson’s RemarksGallen Triana-Baltzer, Ph.D., Senior Scientist, Oncology, CovX Research, Pfizer WRD 

10:45 Leveraging the Molecular Diversity of Large Panel of Cancer Cell Lines to Improve Cancer Therapeutics

Cyril H. Benes, Ph.D., Principal Investigator and Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center

Some of the complexity of cancer is captured by large panels of cancer cell lines. Using high-throughput screening candidate biomarkers of cancer therapeutic sensitivity can be identified.

11:15 Tumor-Derived Cell Lines as a Model System for Discovery of Predictive Biomarkers and Mechanisms of Drug Resistance

Jeffrey Settleman, Ph.D., Senior Director, Discovery Oncology, Genentech

With the emergence of “pathway-targeted” cancer drug therapies, tumor-derived cell lines are playing an increasingly important role in the discovery of biomarkers for stratifying patients for optimal clinical benefit, and to identify molecular mechanisms of innate and acquired drug resistance.

 

Maximizing Success of Preclinical Development 

11:45 Comparative Oncology Modeling of Drug DevelopmentMelissa C. Paoloni, DVM, Director, Comparative Oncology Trials Consortium Comparative Oncology Program, Center for Cancer Research National Cancer Institute, National Institutes of HealthComparative oncology offers an innovative model for improved drug evaluation. This discipline includes the study of cancer biology, its molecular and genetic markers, and most importantly the assessment of novel therapies in companion animals to inform treatment and prevent cancers in human patients.


Champions Oncology12:15 pm Luncheon Presentation I: Utilization of Predictive in vivo TumorGraft Models to Guide Oncology Drug Development Elizabeth Bruckheimer, Ph.D., Vice President, Scientific Operations, Champions Oncology, Inc.One of the challenges of oncology drug development is the ability to translate preclinical results to the clincial setting. By using Champions TumorGraft models, oncology drug developers can better guide a compounds development from the lab to the clinic.

12:45 pm Luncheon Presentation II: (Sponsorship Opportunity Available) or Lunch on Your Own 

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

 

Maximizing Success of Preclinical DevelopmenT (Continued) 

1:40 Chairperson’s RemarksMila McCurrach, Project Manager, NFPC, Neurofibromatosis Pre-Clinical Consortium, Children’s Tumor Foundation, Research Manager, Lustgarten Foundation 

1:45 Pre-Clinical Models for Prediction of Therapeutic Response in Breast Cancer

Joe W. Gray, Ph.D., Gordon Moore Professor and Chair, Biomedical Engineering, Oregon Health and Science University;
Emeritus Professor, UCSF; Visiting Faculty, Lawrence Berkeley National Laboratory; Co-Director, Breast Cancer SPORE

2:15 Maximizing Success of Anticancer Drugs in the Clinic Using Predictive Oncology Pre-Clinical Models

Tycho Heimbach, Ph.D., Associate Director, Novartis Pharmaceuticals Corporation
Efficacious exposure predictions can be challenging due to poor solubility and/or permeability for BDDCS 2/BDDCS 4 anticancer drugs.The successful use of pre-clinical animal data with PBPK/PD/biomarkers together with ACAT modeling to predict systemic exposure or food effects will be presented.

2:45 Developing Foundation/Academic/Pharmaceutical Platforms to Accelerate Pre-Clinical Studies for Rare and Orphan Diseases

Mila McCurrach, Project Manager, NFPC, Neurofibromatosis Pre-Clinical Consortium, Children’s Tumor Foundation, Research Manager, Lustgarten Foundation

Foundations are spearheading, and putting significant resources into, novel platforms that bring together investigators from academic institutions and pharmaceutical companies to rigorously evaluate rational candidate drugs in GEM models.

Vivo Biosciences3:15 New High-Throughput Human MicroTumor Screening Platform To Accelerate Pre-Clinical Drug Development

Raj Singh, Ph.D., President & CEO, Vivo Biosciences, Inc.

VBI’s novel 3D MicroTumor screens replicate monotypic (NCI-60) and heterotypic (PDx) biology and functions. In vivo-like HTS oncology platform allows real-time analysis of drug uptake, tumor penetration and sensitivity profiles, thus accelerating pre-clinical drug development prior to expensive animal trials.

3:30 Sponsored Presentation (Opportunity Available)

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall

(Last Chance to View Posters)

 

Quality of Pre-Clinical Evidence Matters  

4:30 Chairperson’s Remarks

Peter Houghton, Ph.D., Dir., Center for Childhood Cancer, Nationwide Children’s Hospital

4:35 Challenges in Translating Pre-Clinical Research into Benefit for Patients: Raising the Bar for Pre-Clinical Cancer Research

C. Glenn Begley, Ph.D., Senior Vice President, TetraLogic

There are multiple challenges translating research findings into drugs that ultimately benefit patients. Some are inherent in the disease and the models we employ, and are extremely difficult to address.Others are inherent to our processes, and may be more readily overcome.

5:05 Building More Predictive in vitro and in vivo Models to Identify Responder Populations Pre-Clinically

Emma Lees, Ph.D., Vice President, Oncology, NIBR Site Head Emeryville, Novartis Institutes for Biomedical Research

5:35 Challenges to Accurately Translating Results from Pre-Clinical Cancer Models to the Clinic

Peter Houghton, Ph.D., Dir., Center for Childhood Cancer, Nationwide Children’s Hospital

Human tumor xenografts have been the predominant models for cancer drug development for about 30 years. However, there are concerns that results from such pre-clinical models do not translate into clinical reality.

6:05 Panel Discussion: Improving Reproducibility and Predictability of Preclinical ResearchModerator: Peter Houghton, Ph.D., Director, Center for Childhood Cancer, Nationwide Children’s Hospital
Panelists:
C. Glenn Begley, Ph.D., Senior Vice President, TetraLogic
Emma Lees, Ph.D., Vice President, Oncology, NIBR Site Head Emeryville, Novartis Institutes for Biomedical Research
Terry A. Van Dyke, Ph.D., Director, Center for Advanced Preclinical Research (CAPR); Head, Cancer Pathways and Mechanisms Section, Center for Cancer Research, National Cancer Institute
 

6:35 Close of Day

 

Day 1 | Day 2 | Day 3 

 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 Brochure cover 

Premier Sponsors:

Abbott Molecular 

 

Elsevier  


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large